Please assess the completion status of the following clinical trial:

Trial Title: Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Histological/cytological diagnosis of selected locally advanced or metastatic solid tumor~* Demonstrated radiographic progression on most recent tumor assessment imaging~* Have ≥1 measurable lesion as defined by RECIST 1.1 that has not been previously irradiated~* Eastern Cooperative Oncology Group performance status 0-2 for Part 1 and 0-1 for Part 2~* Adequate hematologic, renal, liver, and coagulation functions~* LVEF ≥50% by echocardiogram or MUGA~* Resolved acute effects of any prior therapy~* Participants in Dose Expansion (Part 2) must have ≥2 prior lines of standard of care therapy~* Able to provide tumor tissue for submission to the Sponsor, including mandatory pre-treatment tumor biopsy (adequate archival tissue within the past 1 year is accepted in lieu of new biopsy) for all participants. Participants in Part 2 must also be able to undergo new (de novo) tumor biopsy at baseline (pre-treatment) and on-treatment biopsy until the Sponsor deems that an adequate number of biopsied samples have been received.~Exclusion Criteria:~* Known active symptomatic brain or leptomeningeal metastases requiring steroids.~* Other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ~* Major surgery or radiation therapy within 4 weeks prior to planned first dose~* Last systemic anti-cancer therapy within 4 weeks prior to planned first dose (6 weeks for mitomycin C or nitrosoureas). Participants who received anti-PD-1 therapy require an interval of 90 days prior to first dose~* Participation in other studies involving investigational drug(s) within 4 weeks prior to planned first dose~* Active and clinically significant bacterial, fungal, or viral infection; Hepatitis B or Hepatitis C infection, AIDS-related illness (HIV+ and in good immune health as defined in the protocol may be eligible)~* Active COVID-19/SARS-CoV2~* Anticoagulation with vitamin K antagonists is not allowed~* Active bleeding disorder in the past 6 months prior to first dose~* History of clinically significant severe immune mediated adverse event that was considered related to prior immune modulatory therapy and required immunosuppressive therapy (other than hormone replacement therapy)~* History of interstitial lung disease or pneumonitis~* Organ transplant requiring immunosuppressive treatment or prior allogeneic bone marrow or hematopoietic stem cell transplant~* Pregnant or breastfeeding female participant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Escalation (Part 1) (Type: EXPERIMENTAL): Participants will receive PF-07209960 at escalating dose levels
- Dose Expansion (Part 2) - Cohort 1 (NSCLC) (Type: EXPERIMENTAL): Participants with non-small cell lung cancer (NSCLC) will receive PF-07209960 at the recommended dose from Part 1
- Dose Expansion (Part 2) - Cohort 2 (RCC) (Type: EXPERIMENTAL): Participants with renal cell carcinoma (RCC) will receive PF-07209960 at the recommended dose from Part 1
- Dose Expansion (Part 2) - Cohort 3 (UC) (Type: EXPERIMENTAL): Participants with urothelial carcinoma (UC) will receive PF-07209960 at the recommended dose from Part 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy